| Recruiting | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245 | Jonathan Brammer | Phase 2 |
| Recruiting | Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Ma NCT06699771 | GC Cell Corporation | Phase 1 |
| Recruiting | MB-105 in Patients With CD5 Positive T-cell Lymphoma NCT06534060 | March Biosciences Inc | Phase 2 |
| Recruiting | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Other NCT06561048 | Corvus Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Active Not Recruiting | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant NCT05540340 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas NCT05463263 | Step Pharma, SAS | Phase 1 / Phase 2 |
| Unknown | ChiCGB vs BEAM in High-risk or R/R Lymphomas NCT05466318 | Sichuan University | Phase 3 |
| Unknown | SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies NCT05398614 | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 |
| Unknown | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL NCT05557903 | Lanzhou Institute of Biological Products Co., Ltd | Phase 1 |
| Unknown | Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma NCT04928105 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Completed | CAR-37 T Cells in Hematologic Malignancies NCT04136275 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Withdrawn | Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma NCT04233697 | Columbia University | Phase 1 |
| Recruiting | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas NCT04104776 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma NCT03921879 | Oncotartis, Inc. | Phase 1 |
| Completed | ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy NCT04121507 | GWT-TUD GmbH | Phase 2 |
| Active Not Recruiting | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma NCT03902184 | Innate Pharma | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Re NCT03703375 | Celgene | Phase 3 |
| Recruiting | Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma NCT03161223 | University of Virginia | Phase 1 / Phase 2 |
| Terminated | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or NCT03154710 | Weprom | N/A |
| Completed | Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lym NCT02158975 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma NCT01421667 | Seagen Inc. | Phase 2 |
| Completed | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30- NCT01309789 | Seagen Inc. | Phase 1 |
| Completed | Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma NCT00418535 | Samsung Medical Center | Phase 2 |
| Terminated | UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas NCT00082017 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas NCT00069238 | National Cancer Institute (NCI) | Phase 2 |
| Completed | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) NCT00043368 | Pfizer | Phase 2 |
| Terminated | Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies NCT00038883 | M.D. Anderson Cancer Center | N/A |
| Completed | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies NCT00038376 | M.D. Anderson Cancer Center | Phase 2 |